Financial Performance - The company's operating revenue for 2014 was CNY 239.51 million, representing a 23.71% increase compared to CNY 193.61 million in 2013[18]. - The net profit attributable to shareholders for 2014 was CNY 99.55 million, a 41.08% increase from CNY 70.56 million in 2013[18]. - The company's operating profit for 2014 was CNY 112.41 million, reflecting a 37.60% increase from CNY 81.69 million in 2013[18]. - The cash flow from operating activities for 2014 was CNY 83.70 million, a 43.56% increase compared to CNY 58.30 million in 2013[18]. - The basic earnings per share for 2014 was CNY 0.62, which is a 26.53% increase from CNY 0.49 in 2013[18]. - The company achieved operating revenue of CNY 239,511,105.85 in 2014, representing a year-on-year growth of 23.71%[27]. - Net profit for 2014 was CNY 99,548,645.87, an increase of 41.10% compared to the previous year[28]. - The company's operating profit reached CNY 112,410,351.37, reflecting a growth of 37.60% year-on-year[28]. Assets and Liabilities - The total assets at the end of 2014 reached CNY 531.31 million, up 101.29% from CNY 263.95 million at the end of 2013[18]. - The total liabilities at the end of 2014 were CNY 17.75 million, an increase of 47.51% from CNY 12.04 million at the end of 2013[18]. - The asset-liability ratio at the end of 2014 was 3.34%, a decrease from 4.56% at the end of 2013[18]. - The total cash and cash equivalents increased by 338.22% to 172,138,199.29 yuan in 2014, reflecting improved liquidity[40]. - The company's total assets increased significantly, with cash and cash equivalents making up 51.85% of total assets at the end of 2014, up from 39.15% in 2013[49]. Research and Development - Research and development expenditure amounted to CNY 13,197,407.74, accounting for 5.51% of operating revenue[29]. - The company's R&D investment amounted to 13,197,407.74 yuan in 2014, accounting for 5.51% of operating revenue, a decrease from 6.93% in 2013[38]. - The company completed the first phase of clinical trials for the "Artemisia Powder Drops" project, marking a significant milestone in its product development[27]. - The company is in the clinical trial phase for several new products, including the "Dust Mite Compound" and "Artemisia Flower Powder Drops," aimed at expanding its product line and market competitiveness[37]. - The company has made progress in clinical trials, with the "Dust Mite Drops for Adult Atopic Dermatitis" entering the data analysis phase after completing the second phase of clinical trials[43]. Market and Sales - The market for allergy treatment drugs, particularly dust mite desensitization, is projected to expand to CNY 1.37 billion by 2015, providing a favorable condition for the company's growth[30]. - The sales volume of the "Dust Mite Drops" product reached 2,682,247 units in 2014, representing a year-on-year increase of 15.29% compared to 2,326,564 units in 2013[33]. - The sales volume of the "Dust Mite Skin Prick Diagnostic Kit and related products" increased by 66.98% to 4,864 boxes in 2014, up from 2,913 boxes in 2013, driven by increased awareness among doctors and patients[33]. - The total revenue from sales of "Dust Mite Drops" contributed significantly to the company's market share expansion, attributed to its high safety profile and ease of use[31]. - The company established a comprehensive marketing network covering most provincial cities in China, enhancing product promotion and sales[31]. Financial Management and Dividends - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling RMB 48,480,000 for the year 2014[73]. - The cash dividend represents 100% of the profit distribution total for the year[73]. - The company has maintained a consistent cash dividend policy, with no changes or adjustments reported during the period[73]. - The company is in a growth phase and has significant capital expenditure plans, which influences its dividend distribution strategy[75]. - The company reported a total rental expense of 901,570.81 CNY for the office space leased from Shanghai Xinxing Technology Development Zone, with a rental rate of 1.9 CNY per square meter per day, effective from August 1, 2014, to July 31, 2017[89]. Governance and Compliance - The company has established a comprehensive insider information management system to prevent insider trading[80]. - The company has not experienced any significant changes in its core competitiveness during the reporting period[52]. - The company has not faced any administrative penalties during the reporting period[107]. - The company has complied with all relevant laws and regulations regarding information disclosure, ensuring timely and accurate information for investors[175]. - The company’s board of directors has met multiple times throughout the reporting period, with all meetings conducted in accordance with legal requirements[176]. Shareholder Information - The total number of shareholders at the end of the reporting period was 8,874, compared to 8,800 five trading days before the annual report disclosure[132]. - Zhejiang WoWu Management Consulting holds 51.81% of shares, totaling 83,725,979 shares, with no changes during the reporting period[132]. - The controlling shareholder, Zhejiang WoWu Management Consulting, has not changed during the reporting period[135]. - The company has a lock-up period for shares held by major shareholders, lasting 36 months from the date of listing[137]. - The company has committed to fulfilling its promises regarding the release of restricted shares as per the initial public offering commitments[124].

Financial Performance - Total assets reached CNY 508.33 million, an increase of 92.58% compared to the previous year[7]. - Total revenue for the reporting period was CNY 75.83 million, up 28.91% year-on-year[7]. - Net profit attributable to shareholders was CNY 35.76 million, reflecting a growth of 45.62% compared to the same period last year[7]. - Basic earnings per share increased by 29.41% to CNY 0.22[7]. - The weighted average return on equity was 7.59%, a decrease of 3.32% from the previous year[7]. - The company reported a net cash flow from operating activities of CNY 55.89 million, up 42.92% year-to-date[7]. - The company achieved operating revenue of CNY 75,827,148.94, an increase of CNY 17,007,274.50, or 28.91% year-on-year[24]. - The net profit for the period was 35,757,378.09 CNY, representing 39.73% of the annual net profit target of 90 million CNY[25]. - The company reported a significant increase in prepaid expenses, rising to ¥405,237.80 from ¥5,985,787.71[48]. - Total operating revenue for the current period reached ¥75,827,148.94, an increase of 28.8% compared to ¥58,819,874.44 in the previous period[55]. - Operating profit for the current period was ¥41,418,861.64, a significant increase of 43.3% from ¥28,917,350.15 in the previous period[56]. - Net profit for the current period was ¥35,757,378.09, representing a 45.5% increase compared to ¥24,553,843.56 in the previous period[56]. - Year-to-date total operating revenue reached ¥181,113,447.02, up from ¥146,468,889.97, reflecting a growth of 23.6%[58]. - Year-to-date net profit was ¥75,090,486.83, an increase of 33.9% from ¥56,071,362.77 in the previous period[60]. Shareholder Information - The total number of shareholders at the end of the reporting period was 12,456[13]. - The largest shareholder, WoWu Consulting, holds 51.81% of the shares, totaling 83,725,979 shares[14]. Risks and Challenges - The company faces risks related to high product gross margins and market competition, particularly from competitors developing similar allergy medications[10][11]. - New drug development poses significant risks due to long cycles and unpredictable factors in the biopharmaceutical industry[12]. Cash Flow and Investments - Cash and cash equivalents at the end of the reporting period increased by CNY 151,212,692.22, a growth of 146.33%, mainly due to new share issuance[19]. - The company reported a net cash flow from operating activities of CNY 16,784,084.92, an increase of 42.92% year-on-year, driven by higher cash collections and government subsidies[22]. - The company’s investment income increased by CNY 600,657.55, attributed to returns from entrusted financial products[22]. - The company received CNY 202,916,336.63 from financing activities, indicating strong capital inflow during the quarter[67]. Product Development and Market Strategy - The company plans to leverage the growing market demand for allergy treatments, driven by increasing prevalence and patient awareness[24]. - The "Dust Mite Drops" product has gained market share due to its high safety, non-invasive application, and ease of use, particularly for pediatric patients[25]. - The company received acceptance for the drug registration application of the "House Dust Mite Skin Prick Diagnostic Kit," which will complement existing products and expand the market[25]. - The company is enhancing its product structure in the allergy field through ongoing research and development projects[26]. - The company is improving its sales network and increasing brand awareness through academic promotion and marketing efforts[28]. - The company plans to continue expanding its market presence and investing in new product development to sustain growth[58]. Corporate Governance and Commitments - The company is committed to maintaining internal control systems to ensure the achievement of strategic and operational goals[28]. - The company has not experienced significant changes in its core technology team or major suppliers and customers during the reporting period[25][28]. - The company has adhered to its commitments regarding stock price stability and investor protection as outlined in its prospectus[31]. - The company committed to not transferring or managing its shares for 36 months post-IPO, with a maximum of 25% of shares allowed for transfer annually thereafter[32]. - The company will announce any share reduction three trading days in advance[33]. - The company has committed to maintaining accurate and complete disclosures in its prospectus[33]. - The company has reported that it will announce any share reductions three trading days in advance[34]. - The company has established a clear framework for managing share transfers and lock-up periods to protect investor interests[37]. - The company has committed to ensuring the accuracy and completeness of the prospectus, with a promise to compensate investors for any losses due to false statements or omissions[35]. - The company has not reported any violations of commitments during the reporting period[36]. Fundraising and Use of Proceeds - The total amount of raised funds is CNY 192.38 million, with CNY 4.22 million invested in the current quarter[39]. - Cumulative investment from raised funds amounts to CNY 18.74 million, with a progress rate of 15.73% for the dust mite drop technology renovation project[39]. - The company has received a special fund of CNY 6.17 million from the central government for the "Artemisia annua powder drop" clinical trial project[43]. - CNY 13.8 million of temporarily idle raised funds has been converted into time deposits[41]. - The company has completed the replacement of pre-invested funds totaling CNY 10.97 million for the dust mite drop technology renovation project[41]. - No significant changes in the feasibility of projects or issues with the use of raised funds have been reported[41].

Financial Performance - Total revenue for the first half of 2014 was CNY 105,286,298.08, representing a 20.12% increase compared to CNY 87,649,015.53 in the same period last year[18]. - Net profit attributable to shareholders was CNY 39,339,036.55, up 24.77% from CNY 31,529,778.80 year-on-year[18]. - The net profit after deducting non-recurring gains and losses was CNY 35,575,777.53, reflecting a 14.70% increase from CNY 31,016,079.04 in the previous year[18]. - The net cash flow from operating activities was CNY 32,481,350.30, an increase of 13.01% compared to CNY 28,740,836.20 in the same period last year[18]. - The basic earnings per share increased to CNY 0.25, a 13.64% rise from CNY 0.22 in the previous year[18]. - Operating profit increased to ¥41,159,455.91, up by ¥5,459,489.91 or 15.29% from the previous year[26]. - Net profit for the period was ¥39,333,108.74, reflecting a growth of ¥7,815,589.53 or 24.80% year-over-year[26]. Assets and Equity - Total assets at the end of the reporting period reached CNY 466,963,777.94, a significant increase of 76.91% from CNY 263,954,870.83 at the end of the previous year[18]. - Shareholders' equity attributable to the parent company was CNY 453,336,100.96, up 79.96% from CNY 251,909,850.72 at the end of the previous year[18]. - The company's total assets at the end of the period were 453,339,739.16 CNY[121]. - The total equity attributable to the parent company at the end of the period is 251,919,416.73 CNY[120]. Cash Flow - The total cash and cash equivalents at the end of the period amounted to CNY 265,406,539.72, significantly higher than CNY 85,796,624.33 at the end of the previous period[114]. - Cash generated from operating activities was ¥104,746,907.24, an increase from ¥96,925,524.22 in the prior period[112]. - The net cash flow from investing activities was -CNY 39,839,769.17, worsening from -CNY 5,292,798.67 year-over-year[113]. - Cash inflow from financing activities reached CNY 202,916,336.63, with a net cash flow of CNY 169,425,510.61 after outflows[114]. Market and Competition - The company faces risks related to high product gross margins and market competition, particularly from competitors developing similar products[21][22]. - The market for allergy medications is expanding, driven by increasing prevalence and awareness of allergic diseases among the population[29]. - The company is focusing on expanding its product line in the allergy treatment sector, including new diagnostic and therapeutic products for dust mite allergies[38]. - The company is currently leading the domestic market for desensitization drugs, with a significant growth in the dust mite allergy treatment market[38]. Research and Development - Research and development expenses amounted to ¥7,062,625.82, a slight increase of 2.47% compared to the previous year[28]. - The company is currently conducting clinical trials for new products, including a dust mite compound in phase II and a pollen extract in phase I[36]. - The company is committed to continuous product research and development to strengthen its core competitiveness in the allergy treatment market[39]. - The company plans to expand its product offerings, including the development of oral desensitization drugs and related diagnostic kits[129]. Shareholder and Dividend Policies - The company plans not to distribute cash dividends or issue bonus shares[6]. - A cash dividend of 3 RMB per 10 shares was distributed, totaling 30.3 million RMB, along with a bonus share issuance of 6 shares per 10 shares, increasing total shares to 161.6 million[54]. - The company’s cash dividend policy complies with regulations and has been transparently communicated to shareholders[55]. - The company has a commitment to limit share reductions to 5%-15% of total shares held within two years post-lockup[64]. Fundraising and Investments - The company reported a total fundraising amount of 189.52 million RMB, with 5.85 million RMB and 14.51 million RMB allocated to specific projects[46]. - The company has invested CNY 1.45 million of the total raised funds of CNY 192.38 million, with no changes in the use of these funds[43]. - The company approved the use of up to RMB 60 million of idle funds to purchase bank wealth management products, with an initial investment of RMB 30 million yielding an expected annualized return of 4.8%[7]. Compliance and Governance - The company made commitments regarding the accuracy and completeness of the prospectus, including potential buyback obligations if misstatements occurred[63]. - The company has a long-term commitment to adhere to stock price stabilization plans for newly appointed directors and senior management[63]. - The company has committed to ensuring that any violations of the prospectus commitments will result in the temporary withholding of dividends until obligations are fulfilled[68]. - The company has not encountered any issues with the use of raised funds during the reporting period[54]. Inventory and Receivables - Inventory increased to ¥11,429,034.23 from ¥7,967,485.26, reflecting a growth of approximately 43.5%[99]. - Accounts receivable rose to ¥68,339,067.99 from ¥58,464,144.35, indicating an increase of about 16.1%[99]. - The company uses an aging analysis method to provision for bad debts, with a 5.00% provision for receivables within 1 year, increasing to 100.00% for receivables over 5 years[160]. Financial Instruments and Investments - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, particularly for available-for-sale financial assets with significant declines in fair value[156]. - The company uses the equity method for long-term equity investments in subsidiaries, recognizing investment income based on the investee's net profit[166]. - The company assesses the net realizable value of inventory based on estimated selling prices minus estimated costs and related taxes[162]. Corporate Structure and Changes - The company has undergone significant structural changes since its establishment in 2002, evolving into a publicly listed entity in 2013[130]. - The company did not undergo any changes in its controlling shareholder or actual controller during the reporting period[90]. - The company appointed a new independent director, Lin Xinhua, on May 12, 2014, following the resignation of Wang Deyun[94].

Financial Performance - Total revenue for Q1 2014 was CNY 51,916,319.67, an increase of 20.58% compared to CNY 43,054,120.10 in the same period last year[8]. - Net profit attributable to ordinary shareholders decreased by 17.16% to CNY 13,348,925.99 from CNY 16,114,754.08 year-on-year[8]. - Operating revenue for the period reached CNY 51,916,319.67, an increase of CNY 8,862,199.57 or 20.58% compared to the same period last year[20]. - The company achieved a net profit of CNY 13,348,925.99, representing 14.83% of the annual profit target[23]. - Total profit for the quarter was ¥15,639,319.38, a decline of 16.4% from ¥18,699,889.17 in the prior year[52]. - Net profit for the first quarter was ¥13,342,998.18, down 17.3% from ¥16,107,173.59 in the same period last year[52]. Cash Flow and Liquidity - Operating cash flow for the period was CNY 9,442,207.76, reflecting a 10.96% increase from CNY 8,509,580.03 in the previous year[8]. - Net cash flow from operating activities increased by CNY 932,627.73, a growth of 10.96%, primarily due to increased cash received from sales and reduced tax payments[19]. - Cash and cash equivalents increased by 201.78% to CNY 208,515,478.03 due to new share issuance during the reporting period[17]. - Cash and cash equivalents at the end of the period totaled ¥311,851,891.99, significantly up from ¥69,263,762.38 at the end of the previous period[59]. - The net increase in cash and cash equivalents for the quarter was ¥208,524,267.89, compared to an increase of ¥5,223,781.67 in the same quarter last year, showing a substantial improvement[62]. Assets and Liabilities - Total assets at the end of the period reached CNY 475,857,345.20, an increase of 80.28% from CNY 263,954,870.83 at the end of the previous year[8]. - The company's total liabilities amounted to ¥18,208,006.99, an increase of 51.2% from ¥12,035,454.10[49]. - Shareholder equity attributable to ordinary shareholders rose by 81.67% to CNY 457,645,700.01 from CNY 251,909,850.72 year-on-year[8]. - The company's total current assets reached 404.74 million RMB, compared to 195.08 million RMB at the beginning of the period, indicating strong liquidity growth[44]. Expenses - Management expenses rose by CNY 7,541,550.90, a significant increase of 123.08%, mainly due to higher R&D and public relations costs[18]. - Total operating costs for Q1 2014 were ¥36,969,181.79, up 49.2% from ¥24,755,488.12 in Q1 2013[51]. - Sales expenses increased to ¥20,554,309.33, up 25.5% from ¥16,329,922.91 in the previous year[54]. Market and Competition - The company faces risks related to high product gross margins and market competition, particularly from competitors developing similar products[10][11]. - The market for allergic diseases is expanding, driving effective demand for products and contributing to revenue growth[20]. - The company has established a marketing network covering most provincial cities in China, enhancing product sales[21]. - The company’s "Dust Mite Drops" product has gained market share due to its safety and ease of use, particularly among children[21]. Shareholder and Stock Management - The company has committed to not transferring or entrusting its shares for 36 months post-IPO, with a maximum annual transfer limit of 25% of its total shares held[26]. - If the company's stock price remains below the net asset value per share for three years post-IPO, the company will initiate stock price stabilization measures[26]. - The company plans to reduce its shareholding by 5%-15% within two years after the lock-up period if the stock price is above the issue price[27]. - The company will publicly announce any share reductions three trading days in advance[27]. - The company committed to ensuring the accuracy and completeness of its prospectus, promising to compensate investors for any losses due to false statements or omissions[29]. Fundraising and Investment - Total fundraising amount reached CNY 192.38 million, with CNY 66,700 invested in the current quarter[34]. - The company reported a total fundraising amount of 19,238.41 million RMB, with 253.38 million RMB invested by the end of the reporting period, representing an investment progress of approximately 1.32%[35]. - The company has not achieved the expected benefits from its investment projects, with the annual production project of 3 million dust mite solutions showing a completion rate of only 9.48%[35]. - The company has not encountered any issues regarding the use of raised funds during the reporting period[36].

Financial Performance - The company's operating revenue for 2013 was CNY 193,609,754.28, representing a 31.25% increase compared to CNY 147,517,280.49 in 2012[17]. - Operating profit for 2013 reached CNY 81,691,790.07, a growth of 35.34% from CNY 60,359,777.00 in the previous year[17]. - The net profit attributable to shareholders was CNY 70,564,349.31, marking a 31.22% increase from CNY 53,773,772.09 in 2012[17]. - Basic earnings per share for 2013 were CNY 0.78, a 30% increase from CNY 0.60 in the previous year[17]. - The net profit for 2013 was CNY 70,551,111.57, which is a 31.21% increase from CNY 53,769,213.79 in 2012[29]. - The gross profit margin remained high, but there are risks associated with potential changes in procurement prices and market conditions affecting sustained growth[21]. - The company achieved a net cash flow from operating activities of CNY 58,303,540.11, indicating strong cash flow management[31]. - Operating cash inflow increased by 34.08% year-on-year to ¥212,587,378.32, driven by sales growth and good collection of receivables[47]. - Operating cash outflow rose by 31.43% year-on-year to ¥154,283,838.21, mainly due to increased employee compensation and market expansion costs[47]. - Net cash flow from operating activities grew by 41.63% year-on-year to ¥58,303,540.11, attributed to sales growth and improved cost control[47]. Assets and Liabilities - The company's total assets increased by 38.11% to CNY 263,954,870.83 at the end of 2013, up from CNY 191,113,274.99 in 2012[17]. - The company's total liabilities at the end of 2013 were CNY 12,035,454.10, which is a 23.65% increase from CNY 9,733,266.22 in 2012[17]. - The weighted average return on equity was 32.57% in 2013, slightly down from 34.81% in 2012[17]. - The company's asset-liability ratio improved to 4.56% in 2013 from 5.09% in 2012[17]. - The net assets attributable to shareholders increased by 38.9% to CNY 251,909,850.72 at the end of 2013, compared to CNY 181,357,205.02 in 2012[17]. - Cash and cash equivalents increased by 78.11% year-on-year to ¥39,281,414.90, due to higher operating cash flow and reduced financing outflows[48]. - Total assets increased, with cash and cash equivalents representing 39.15% of total assets, up from 33.52% in the previous year[55]. Research and Development - Research and development expenses increased by 78.74% in 2013, amounting to CNY 13,416,111.37, reflecting the company's commitment to innovation[29]. - Research and development (R&D) investment amounted to 13,416,111.37 yuan in 2013, representing 6.93% of operating revenue, up from 5.09% in 2012[45]. - The company is conducting clinical trials for new products, including a dust mite compound for allergic rhinitis and asthma, which aims to enhance product offerings and market competitiveness[44]. - The company plans to enhance its R&D capabilities and product offerings in the allergy treatment and diagnosis sector, focusing on independent innovation[65]. Market and Competition - The main product, "Dust Mite Drops," accounted for 97.13% of total revenue in 2013, highlighting the risk of product concentration[20]. - The company is facing potential market competition as competitors are conducting clinical trials for similar products[23]. - The company’s production capacity for "Dust Mite Drops" is set to increase significantly, raising concerns about potential overcapacity if market demand does not meet expectations[22]. - The company has been recognized as a high-tech enterprise, which provides tax benefits until the end of 2014, but risks exist if this status is not renewed[25]. - The company is experiencing intense market competition as the incidence of allergic diseases rises and foreign competitors enter the market[71]. Sales and Marketing - The sales volume of the "Dust Mite Drops" increased by 30.14% year-on-year, reaching 2,326,564 units in 2013, driven by reduced product dropout rates and an expanding market size[39]. - The production volume of "Dust Mite Drops" grew by 50.34% year-on-year to 2,872,082 units, reflecting increased capacity to meet rising market demand[39]. - The inventory of "Dust Mite Drops" surged by 166.11% year-on-year, totaling 860,456 units, to maintain adequate stock levels in response to increased sales[39]. - The marketing network has expanded to cover most provincial cities in China, supported by experienced sales personnel and ongoing procurement initiatives[37]. - Sales expenses increased by 35.39% year-on-year to 75,726,456.32 yuan, primarily due to the expansion of the sales team to increase market share[43]. Governance and Compliance - The company has established a strict insider information management system, ensuring no insider trading incidents occurred during the reporting period[86]. - The governance structure ensures equal rights for all shareholders, particularly minority shareholders, in decision-making processes[149]. - The company has implemented internal control measures to enhance governance and compliance with relevant laws and regulations[148]. - The company has committed to timely and accurate information disclosure, ensuring all investors have equal access to company information[156]. - The company has established a transparent performance evaluation and incentive mechanism for directors and senior management, ensuring compliance with relevant laws and regulations[153]. Shareholder and Dividend Policies - The company has established a profit distribution policy prioritizing cash dividends, aiming to distribute at least 30% of the distributable profits as cash dividends[75]. - The cash dividend distribution plan includes a cash dividend of RMB 3.00 per 10 shares, totaling RMB 30,300,000, which represents 33.33% of the total profit distribution[80]. - The cash dividend payout ratio for 2013 is 42.94% of the net profit attributable to ordinary shareholders[85]. - The company has not distributed any cash dividends in the previous two years (2011 and 2012) due to its developmental stage[83]. - The company is in a growth phase and has significant capital expenditure plans, ensuring that cash dividends will not be less than 20% of the profit distribution in the future[80]. Risks and Challenges - The company faces risks from a slow global economic recovery and a slowdown in China's economic growth, which may adversely affect the pharmaceutical industry[69]. - The company is challenged by increased R&D costs and longer approval cycles due to stricter national drug registration policies[70]. - The company has ongoing applications for 4 domestic invention patents, indicating a focus on innovation[59]. Employee and Management Structure - The total number of employees as of December 31, 2013, is 560, with sales personnel constituting 66.07% of the workforce[142]. - The company reported a total remuneration of 207.45 million CNY for directors, supervisors, and senior management during the reporting period[139]. - The company has a core technical team of 5 members, all with over 3 years of tenure, following the departure of a key technical personnel in May 2013[141]. - The employee educational background shows that 47 employees (8.39%) hold a master's degree or higher, while 266 employees (47.50%) have a bachelor's degree[143]. - The age distribution indicates that 80.71% of employees are 30 years old or younger[144].